These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 4038580)

  • 21. The use of aztreonam in pediatric patients: a review.
    Bosso JA; Black PG
    Pharmacotherapy; 1991; 11(1):20-5. PubMed ID: 1902290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aztreonam.
    Tunkel AR; Scheld WM
    Infect Control Hosp Epidemiol; 1990 Sep; 11(9):486-94. PubMed ID: 2230052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of empiric aztreonam and aminoglycoside regimens in the treatment of serious gram-negative lower respiratory infections.
    Bjornson HS; Ramirez-Ronda C; Saavedra S; Rivera-Vázquez CR; Liu C; Hinthorn DR
    Clin Ther; 1993; 15(1):65-78. PubMed ID: 8458056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tobramycin sulfate: a summary of worldwide experience from clinical trials.
    Bendush CL; Weber R
    J Infect Dis; 1976 Aug; 134 Suppl():S219-34. PubMed ID: 787450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients.
    Trujillo H; Harry N; Arango A; Benítez G; Restrepo F; Mejía GI; Castrillón AL
    Chemotherapy; 1989; 35 Suppl 1():25-30. PubMed ID: 2731447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections.
    Rodriguez JR; Ramirez-Ronda CH
    Am J Med; 1985 Feb; 78(2A):42-3. PubMed ID: 4038578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful response of severe neonatal gram-negative infection to treatment with aztreonam.
    Constantopoulos A; Thomaidou L; Loupa H; Papoulias G
    Chemotherapy; 1989; 35 Suppl 1():101-5. PubMed ID: 2731446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with aztreonam in four Mediterranean countries.
    Daikos GK
    Rev Infect Dis; 1985; 7 Suppl 4():S831-5. PubMed ID: 2934787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The role of carbapenems in the treatment of nosocomial infection].
    Martínez Lacasa J; Garau J
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():78-85. PubMed ID: 9410075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli.
    Simons WJ; Lee TJ
    Rev Infect Dis; 1985; 7 Suppl 4():S783-8. PubMed ID: 2934786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do we need the third-generation cephalosporins?
    Neu HC
    J Antimicrob Chemother; 1984 Sep; 14 Suppl B():1-12. PubMed ID: 6501133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aztreonam therapy for serious gram-negative infections in children.
    Stutman HR; Chartrand SA; Tolentino T; Friedhoff L; Marks MI
    Am J Dis Child; 1986 Nov; 140(11):1147-51. PubMed ID: 3766490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aztreonam in the prevention and treatment of infection in neutropenic cancer patients.
    Rolston KV; Bodey GP; Elting L
    Am J Med; 1990 Mar; 88(3C):24S-29S; discussion 38S-42S. PubMed ID: 2180294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moxalactam: clinical summary of efficacy and safety.
    Kammer RB
    Rev Infect Dis; 1982; 4 Suppl():S712-9. PubMed ID: 6218589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experience with ceftizoxime: an overall summary of clinical trials in Japan.
    Shimada J; Shimizu K
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():311-26. PubMed ID: 6296026
    [No Abstract]   [Full Text] [Related]  

  • 37. Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Romankiewicz JA; Speight TM; Avery GS
    Drugs; 1983 Oct; 26(4):279-333. PubMed ID: 6354685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of serious gram-negative infections with aztreonam.
    Greenberg RN; Reilly PM; Luppen KL; McMillian R; Bollinger M; Wolk SM; Darji TB; Noorani AA
    J Infect Dis; 1984 Nov; 150(5):623-30. PubMed ID: 6541672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
    Hellinger WC; Brewer NS
    Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical use of aztreonam.
    Schönwald S; Schoss-Vidensek Z; Car V; Krznar B
    Chemotherapy; 1989; 35 Suppl 1():45-8. PubMed ID: 2731450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.